https://www.selleckchem.com/pr....oducts/n-formyl-met-
C who progress to new standard ICI-based regimens. Although the INMUNOSUN trial did not reach the pre-specified endpoint, it demonstrated that sunitinib is active and can be safely used as a second-line option in patients with mRCC who progress to new standard ICI-based regimens. Previous studies on the prevalence and predictors of postpartum depression (PPD) in China were mostly hospital-based with relatively small study samples. Basing on a routine screening programme, this study assessed the prevalence and factors a
Curtir
Comentario
Compartilhar
